# US 8,784,797 B2 · Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,797 B2
- Document ID: US8784797B2
- Status: Granted
- Kind: B2
- Application number: 13/515,322
- Filed: 2009-12-15
- Published: 2013-01-03
- Granted: 2014-07-22
- Earliest claimed: 2009-12-15
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm); American University of Brirut
- Applicants: Hugues De The; Ali Bazarbachi; Olivier Hermine
- Inventors: Hugues De The; Ali Bazarbachi; Olivier Hermine
- Web page: https://patentgrep.com/patent/US8784797B2

## CPC

- A61K 38/212: {IFN-alpha}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61K 33/36: Arsenic; Compounds thereof
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/21: Interferons {[IFN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.

## Claims

### Claim 1

A method for treating Adult T-cell leukemia/lymphoma in a patient in need thereof, comprising
administering to said subject a dose from 1 to 20 million international units (MIU) per day of an interferon-alpha, a dose from 1 to 50 mg per day of arsenic trioxide and a dose from 1 to 1500 mg per kg of body weight per day of zidovudine.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said arsenic trioxide is administered at a dose from 10 to 15 mg per day.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said zidovudine is administered at a dose from 600 to 1000 mg per kg of body weight per day.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said interferon-alpha is administered at a dose from 3 to 9 MIU per day.

### Claim 5 (depends on 1)

The method according to claim 1 wherein said arsenic trioxide is administered by an intravenous route, said zidovudine is administered by an oral route, and said interferon-alpha is administered by an intramuscular or subcutaneous route.

### Claim 6 (depends on 1)

The method according to claim 1 wherein said interferon-alpha, said arsenic trioxide and said zidovudine are administered as a combined preparation for simultaneous, separate or sequential use.